Search Orphan Drug Designations and Approvals
-
Generic Name: | atezolizumab | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Tecentriq | ||||||||||||||||
Date Designated: | 10/08/2020 | ||||||||||||||||
Orphan Designation: | treatment of soft tissue sarcoma | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Genentech, Inc. 1 DNA Way South San Francisco, California 94080-4990 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | atezolizumab |
---|---|---|
Trade Name: | Tecentriq | |
Marketing Approval Date: | 12/09/2022 | |
Approved Labeled Indication: | as a single agent for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS) | |
Exclusivity End Date: | 12/09/2029 | |
Exclusivity Protected Indication* : | treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS) | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-